|
1
|
Smolarz B, Łukasiewicz H, Samulak D,
Piekarska E, Kołaciński R and Romanowicz H: Lung
cancer-epidemiology, pathogenesis, treatment and molecular aspect
(review of literature). Int J Mol Sci. 26:20492025. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhang Z, Zhang S, Xu Y, Liu X and Dong W:
The differences in the distribution characteristics and prognostic
value of tumor-infiltrating T lymphocyte subsets between lung
adenocarcinoma and lung squamous cell carcinoma. Chin Clin Oncol.
13:832024. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cunningham R and Hansen CG: The Hippo
pathway in cancer: YAP/TAZ and TEAD as therapeutic targets in
cancer. Clin Sci (Lond). 136:197–222. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Qin M, Geng E, Wang J, Yu M, Dong T, Li S,
Zhang X, Lin J, Shi M, Li J, et al: LATS2 condensates organize
signalosomes for Hippo pathway signal transduction. Nat Chem Biol.
20:710–720. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Abou Nader N, Charrier L, Meisnsohn MC,
Banville L, Deffrennes B, St-Jean G, Boerboom D, Zamberlam G,
Brind'Amour J, Pépin D and Boyer A: Lats1 and Lats2 regulate YAP
and TAZ activity to control the development of mouse Sertoli cells.
FASEB J. 38:e236332024. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kastan N, Gnedeva K, Alisch T, Petelski
AA, Huggins DJ, Chiaravalli J, Aharanov A, Shakked A, Tzahor E,
Nagiel A, et al: Small-molecule inhibition of Lats kinases may
promote Yap-dependent proliferation in postmitotic mammalian
tissues. Nat Commun. 12:31002021. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Furth N, Pateras IS, Rotkopf R, Vlachou V,
Rivkin I, Schmitt I, Bakaev D, Gershoni A, Ainbinder E, Leshkowitz
D, et al: LATS1 and LATS2 suppress breast cancer progression by
maintaining cell identity and metabolic state. Life Sci Alliance.
1:e2018001712018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhu M, Liao G, Wang Y, Mo J, Yi D, Zhang Y
and Xian L: Identifying LATS2 as a prognostic biomarker relevant to
immune infiltrates in human esophageal squamous cell carcinoma.
Front Genet. 13:9525282022. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wu A, Li J, Wu K, Mo Y, Luo Y, Ye H, Mai
Z, Guo K, Wang Y, Li S, et al: LATS2 as a poor prognostic marker
regulates non-small cell lung cancer invasion by modulating MMPs
expression. Biomed Pharmacother. 82:290–297. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tang Z, Li C, Kang B, Gao G, Li C and
Zhang Z: GEPIA: A web server for cancer and normal gene expression
profiling and interactive analyses. Nucleic Acids Res. 45((W1)):
W98–W102. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tomczak K, Czerwinska P and Wiznerowicz M:
The cancer genome atlas (TCGA): An immeasurable source of
knowledge. Contemp Oncol (Pozn). 19:A68–A77. 2015.PubMed/NCBI
|
|
12
|
Liu CJ, Hu FF, Xie GY, Miao YR, Li XW,
Zeng Y and Guo AY: GSCA: An integrated platform for gene set cancer
analysis at genomic, pharmacogenomic and immunogenomic levels.
Brief Bioinform. 24:bbac5582023. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Uhlén M, Fagerberg L, Hallström BM,
Lindskog C, Oksvold P, Mardinoglu A, Sivertsson Å, Kampf C,
Sjöstedt E, Asplund A, et al: Proteomics. Tissue-based map of the
human proteome. Science. 347:12604192015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Uhlen M, Oksvold P, Fagerberg L, Lundberg
E, Jonasson K, Forsberg M, Zwahlen M, Kampf C, Wester K, Hober S,
et al: Towards a knowledge-based human protein atlas. Nat
Biotechnol. 28:1248–1250. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Love MI, Huber W and Anders S: Moderated
estimation of fold change and dispersion for RNA-seq data with
DESeq2. Genome Biol. 15:5502014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhou Y, Zhou B, Pache L, Chang M,
Khodabakhshi AH, Tanaseichuk O, Benner C and Chanda SK: Metascape
provides a biologist-oriented resource for the analysis of
systems-level datasets. Nat Commun. 10:15232019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen B, Khodadoust MS, Liu CL, Newman AM
and Alizadeh AA: Profiling tumor infiltrating immune cells with
CIBERSORT. Methods Mol Biol. 1711:243–259. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Therneau YM and Grambsch PM: Modeling
survival data: Extending the cox model. Springer; New York: pp.
7–37. 2000
|
|
20
|
Zhong Z, Jiao Z and Yu FX: The Hippo
signaling pathway in development and regeneration. Cell Rep.
43:1139262024. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu L, Huang S, Du Y, Zhou H, Zhang K and
He J: Lats2 deficiency protects the heart against myocardial
infarction by reducing inflammation and inhibiting mitochondrial
fission and STING/p65 signaling. Int J Biol Sci. 19:3428–3440.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yuan T, Annamalai K, Naik S, Lupse B,
Geravandi S, Pal A, Dobrowolski A, Ghawali J, Ruhlandt M, Gorrepati
KDD, et al: The Hippo kinase LATS2 impairs pancreatic β-cell
survival in diabetes through the mTORC1-autophagy axis. Nat Commun.
12:49282021. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liang H, Xu Y, Zhao J, Chen M and Wang M:
Hippo pathway in non-small cell lung cancer: Mechanisms, potential
targets, and biomarkers. Cancer Gene Ther. 31:652–666. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Malik SA, Khan MS, Dar M, Hussain MU, Shah
MA, Shafi SM and Mudassar S: Molecular alterations and expression
dynamics of LATS1 and LATS2 genes in non-small-cell lung carcinoma.
Pathol Oncol Res. 24:207–214. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Matsuda T, Miyata Y, Nakamura Y, Otsubo A,
Mukae Y, Harada J, Mitsunari K, Matsuo T, Ohba K, Furusato B and
Sakai H: Pathological significance and prognostic role of LATS2 in
prostate cancer. Prostate. 81:1252–1260. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang Y, Hu CF, Chen J, Yan LX, Zeng YX
and Shao JY: LATS2 is de-methylated and overexpressed in
nasopharyngeal carcinoma and predicts poor prognosis. BMC Cancer.
10:5382010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sun N, Tan BB and Li Y: Nomogram model
including LATS2 expression was constructed to predict the prognosis
of advanced gastric cancer after surgery. World J Gastrointest
Surg. 16:518–528. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Xie Y, Lv Y, Zhang Y, Liang Z, Han L and
Xie Y: LATS2 promotes apoptosis in non-small cell lung cancer A549
cells via triggering Mff-dependent mitochondrial fission and
activating the JNK signaling pathway. Biomed Pharmacother.
109:679–689. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yao F, Liu H, Li Z, Zhong C and Fang W:
Down-regulation of LATS2 in non-small cell lung cancer promoted the
growth and motility of cancer cells. Tumour Biol. 36:2049–2057.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang L, Li S, Wang R, Chen C, Ma W and
Cai H: Anti-tumor effect of LATS2 on liver cancer death: Role of
DRP1-mediated mitochondrial division and the Wnt/β-catenin pathway.
Biomed Pharmacother. 114:1088252019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Shi Y, Geng D, Zhang Y, Zhao M, Wang Y,
Jiang Y, Yu R and Zhou X: LATS2 inhibits malignant behaviors of
glioma cells via inactivating YAP. J Mol Neurosci. 68:38–48. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chen Y, Yu D, Qian H, Shi Y and Tao Z:
CD8+ T cell-based cancer immunotherapy. J Transl Med.
22:3942024. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Qayoom H, Sofi S and Mir MA: Targeting
tumor microenvironment using tumor-infiltrating lymphocytes as
therapeutics against tumorigenesis. Immunol Res. 71:588–599. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Park J, Hsueh PC, Li Z and Ho PC:
Microenvironment-driven metabolic adaptations guiding
CD8+ T cell anti-tumor immunity. Immunity. 56:32–42.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zander R, Schauder D, Xin G, Nguyen C, Wu
X, Zajac A and Cui W: CD4+ T cell help is required for
the formation of a cytolytic CD8+ T cell subset that
protects against chronic infection and cancer. Immunity.
51:1028–1042.e4. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Giatromanolaki A, Anestopoulos I,
Panayiotidis MI, Mitrakas A, Pappa A and Koukourakis MI: Prognostic
relevance of the relative presence of CD4, CD8 and CD20 expressing
tumor infiltrating lymphocytes in operable non-small cell lung
cancer patients. Anticancer Res. 41:3989–3995. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Tao Y and Xie Y: Prognostic impact of CD4+
and CD8+ tumor-infiltrating lymphocytes in patients with colorectal
cancer. Acta Chir Belg. 124:35–40. 2024.PubMed/NCBI
|
